RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Synthesis of hemopressin by [(2+2+2+1)+2] segment condensation
Reddy, P., McElroy, KT., McElhinny, C., Lewin, A., & Carroll, F. (2009). Synthesis of hemopressin by [(2+2+2+1)+2] segment condensation. In M. Lebl (Ed.), Peptides: Breaking away (pp. 42-43). http://www.5z.com/21staps/Proc21stAPS_CD_v8.pdf
Hemopressin (HP), a naturally occurring nonapeptide (Pro-Val-Asn-Phe-Lys-Phe-Leu-Ser-His-OH) derived from the alpha-chain of hemoglobin[1] has recently been identified as an endogenous selective CB1 antagonist [2]. Because of widespread interest [3] in this bioactive nonapeptide, which is reported to have been synthesized using solid phase Fmoc chemistry [1b], the National Institute on Drug Abuse (NIDA) authorized the solution phase synthesis of HP as part of its Drug Synthesis Program. The fragment condensation approach involves peptides fragments derived from synthetic intermediates that can also be used in possible structure-activity studies.